Discovery Platform

Dualogics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

INDIA India

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech Partners

Lead Product(s): IgG-like bispecific antibodies

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Large molecule

Partner/Sponsor/Collaborator: AbCellera

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition August 20, 2020

Details:

Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing internal assets and to complete existing partnership programs.

Secarna Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

GERMANY Germany

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

Secarna, Evotec Form Strategic Antisense Alliance

Lead Product(s): Antisense oligonucleotide therapy

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Large molecule

Partner/Sponsor/Collaborator: Evotec

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership August 05, 2020

Details:

Partnership creates an opportunity for biotech and pharmaceutical companies to enter the growing field of antisense therapeutics by partnering with Evotec and Secarna and to gain access to the companies' co-owned pipeline through a variety of individual deal structures.

Seattle Children’s Research Institute

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

GentiBio Inks Licensing Agreement with Seattle Children’s Research Institute to Develop Engineered Regulatory T cells to Deliver Immune To...

Lead Product(s): Engineered Regulatory T cell therapy

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Gentbio

Deal Size: $20.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 05, 2020

Details:

Under the terms of the licensing agreements, Seattle Children’s, BRI and MIGAL will exclusively licenseunique technologies to GentiBio that overcome many of the current limitations of Tregs therapeutics,including rarity and plasticity of endogenous Tregs populations.

AgeX Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

ESMO 2020 Congress

Participation Not Confirmed

Update your events

AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells

Lead Product(s): Hypoimmunogenic cells

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 29, 2020

Details:

First research collaboration for immunotolerance UniverCyteTM technology platform, marking launch of new business development and collaboration strategy.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Dualogics

AbCellera Acquires OrthoMab Bispecific Platform to Propel the Development of Antibody Therapies for Pharma and Biotech Partners

Secarna Pharma

Secarna, Evotec Form Strategic Antisense Alliance

Seattle Children’s Research Institute

GentiBio Inks Licensing Agreement with Seattle Children’s Research Institute to Develop Engineered Regulatory T cells to Deliver Immune To...

AgeX Therapeutics

AgeX Therapeutics Enters Research Collaboration With Japanese Biopharma Company to Generate Hypoimmunogenic Cells